Skip to content

Study · Animal study (in vivo) · mouse · 2014

10 results

Supplementation with carnosine decreases plasma triglycerides and modulates atherosclerotic plaque composition in diabetic apo E(-/-) mice.

Brown BE, Kim CH, Torpy FR, Bursill CA, McRobb LS, Heather AK, Davies MJ, van Reyk DM

Atherosclerosis18 Dec 2013Cited by 49 (Europe PMC)

PMID24468155 (opens in a new tab)DOI10.1016/j.atherosclerosis.2013.11.068 (opens in a new tab)PepBankPUB-24468155
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In mice, carnosine supplementation significantly increased plasma carnosine approximately 20-fold.

    In plain wordsIn mice, carnosine supplementation increased blood carnosine compared with no supplementation.

    Peptide
    L-carnosine
    Outcome
    IncreasePlasma carnosine
    Study

    micen: not reported in source

    diabetic apo E(-/-) mice and non-diabetic mice
    Comparator
    no carnosine supplementation
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    2g/L · drinking water · 20 weeksAs given in this study (mice).

    Source sentences

    Summary
    Prolonged carnosine supplementation resulted in a significant (∼20-fold) increase in plasma carnosine levels, and a significant (∼23%) lowering of triglyceride levels in the carnosine-supplemented groups regardless of glycaemic status.
    2 context sentences
    Summary · context
    Streptozotocin-induced diabetic apo E(-/-) mice were maintained for 20 weeks, post-induction of diabetes.
    Summary · context
    Half of the animals received carnosine (2g/L) in their drinking water.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, carnosine significantly lowered triglycerides by approximately 23% regardless of glycaemic status.

    In plain wordsIn mice, carnosine lowered blood triglycerides compared with no supplementation.

    Peptide
    L-carnosine
    Outcome
    DecreasePlasma triglycerides
    Study

    micen: not reported in source

    diabetic apo E(-/-) mice and non-diabetic mice
    Comparator
    no carnosine supplementation
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    2g/L · drinking water · 20 weeksAs given in this study (mice).

    Source sentences

    Summary
    Prolonged carnosine supplementation resulted in a significant (∼20-fold) increase in plasma carnosine levels, and a significant (∼23%) lowering of triglyceride levels in the carnosine-supplemented groups regardless of glycaemic status.
    2 context sentences
    Summary · context
    Streptozotocin-induced diabetic apo E(-/-) mice were maintained for 20 weeks, post-induction of diabetes.
    Summary · context
    Half of the animals received carnosine (2g/L) in their drinking water.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice, carnosine supplementation did not affect glycaemic status.

    In plain wordsIn mice, carnosine did not affect blood sugar status compared with no supplementation.

    Peptide
    L-carnosine
    Outcome
    No significant changeGlycaemic status
    Study

    micen: not reported in source

    diabetic apo E(-/-) mice and non-diabetic mice
    Comparator
    no carnosine supplementation
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2g/L · drinking water · 20 weeksAs given in this study (mice).

    Source sentences

    Summary
    Supplementation did not affect glycaemic status, blood cholesterol levels or loss of body mass.
    2 context sentences
    Summary · context
    Streptozotocin-induced diabetic apo E(-/-) mice were maintained for 20 weeks, post-induction of diabetes.
    Summary · context
    Half of the animals received carnosine (2g/L) in their drinking water.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice, carnosine supplementation did not affect blood cholesterol.

    In plain wordsIn mice, carnosine did not affect blood cholesterol compared with no supplementation.

    Peptide
    L-carnosine
    Outcome
    No significant changeBlood cholesterol
    Study

    micen: not reported in source

    diabetic apo E(-/-) mice and non-diabetic mice
    Comparator
    no carnosine supplementation
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    2g/L · drinking water · 20 weeksAs given in this study (mice).

    Source sentences

    Summary
    Supplementation did not affect glycaemic status, blood cholesterol levels or loss of body mass.
    2 context sentences
    Summary · context
    Streptozotocin-induced diabetic apo E(-/-) mice were maintained for 20 weeks, post-induction of diabetes.
    Summary · context
    Half of the animals received carnosine (2g/L) in their drinking water.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice, carnosine supplementation did not affect loss of body mass.

    In plain wordsIn mice, carnosine did not affect body mass loss compared with no supplementation.

    Peptide
    L-carnosine
    Outcome
    No significant changeBody mass loss
    Study

    micen: not reported in source

    diabetic apo E(-/-) mice and non-diabetic mice
    Comparator
    no carnosine supplementation
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2g/L · drinking water · 20 weeksAs given in this study (mice).

    Source sentences

    Summary
    Supplementation did not affect glycaemic status, blood cholesterol levels or loss of body mass.
    2 context sentences
    Summary · context
    Streptozotocin-induced diabetic apo E(-/-) mice were maintained for 20 weeks, post-induction of diabetes.
    Summary · context
    Half of the animals received carnosine (2g/L) in their drinking water.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, carnosine did not diminish measured plaque area.

    In plain wordsIn diabetic mice, carnosine did not reduce plaque area compared with no supplementation.

    Peptide
    L-carnosine
    Outcome
    No significant changePlaque area
    Study

    micen: not reported in source

    diabetic apo E(-/-) mice and non-diabetic mice
    Comparator
    no carnosine supplementation
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    2g/L · drinking water · 20 weeksAs given in this study (mice).

    Source sentences

    Summary
    In the diabetic mice, carnosine supplementation did not diminish measured plaque area, but reduced the area of plaque occupied by extracellular lipid (∼60%) and increased both macrophage numbers (∼70%) and plaque collagen content (∼50%).
    2 context sentences
    Summary · context
    Streptozotocin-induced diabetic apo E(-/-) mice were maintained for 20 weeks, post-induction of diabetes.
    Summary · context
    Half of the animals received carnosine (2g/L) in their drinking water.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, carnosine reduced plaque area occupied by extracellular lipid by approximately 60%.

    In plain wordsIn diabetic mice, carnosine reduced plaque fat area compared with no supplementation.

    Peptide
    L-carnosine
    Outcome
    DecreasePlaque extracellular lipid area
    Study

    micen: not reported in source

    diabetic apo E(-/-) mice and non-diabetic mice
    Comparator
    no carnosine supplementation
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    2g/L · drinking water · 20 weeksAs given in this study (mice).

    Source sentences

    Summary
    In the diabetic mice, carnosine supplementation did not diminish measured plaque area, but reduced the area of plaque occupied by extracellular lipid (∼60%) and increased both macrophage numbers (∼70%) and plaque collagen content (∼50%).
    2 context sentences
    Summary · context
    Streptozotocin-induced diabetic apo E(-/-) mice were maintained for 20 weeks, post-induction of diabetes.
    Summary · context
    Half of the animals received carnosine (2g/L) in their drinking water.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, carnosine increased plaque macrophage numbers by approximately 70%.

    In plain wordsIn diabetic mice, carnosine increased plaque macrophage numbers compared with no supplementation.

    Peptide
    L-carnosine
    Outcome
    IncreasePlaque macrophage numbers
    Study

    micen: not reported in source

    diabetic apo E(-/-) mice and non-diabetic mice
    Comparator
    no carnosine supplementation
    Outcome group
    Immune response · Cardiovascular
    Studied dose
    2g/L · drinking water · 20 weeksAs given in this study (mice).

    Source sentences

    Summary
    In the diabetic mice, carnosine supplementation did not diminish measured plaque area, but reduced the area of plaque occupied by extracellular lipid (∼60%) and increased both macrophage numbers (∼70%) and plaque collagen content (∼50%).
    2 context sentences
    Summary · context
    Streptozotocin-induced diabetic apo E(-/-) mice were maintained for 20 weeks, post-induction of diabetes.
    Summary · context
    Half of the animals received carnosine (2g/L) in their drinking water.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, carnosine increased plaque collagen content by approximately 50%.

    In plain wordsIn diabetic mice, carnosine increased plaque collagen compared with no supplementation.

    Peptide
    L-carnosine
    Outcome
    IncreasePlaque collagen content
    Study

    micen: not reported in source

    diabetic apo E(-/-) mice and non-diabetic mice
    Comparator
    no carnosine supplementation
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    2g/L · drinking water · 20 weeksAs given in this study (mice).

    Source sentences

    Summary
    In the diabetic mice, carnosine supplementation did not diminish measured plaque area, but reduced the area of plaque occupied by extracellular lipid (∼60%) and increased both macrophage numbers (∼70%) and plaque collagen content (∼50%).
    2 context sentences
    Summary · context
    Streptozotocin-induced diabetic apo E(-/-) mice were maintained for 20 weeks, post-induction of diabetes.
    Summary · context
    Half of the animals received carnosine (2g/L) in their drinking water.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, carnosine did not significantly increase plaque alpha-actin-positive smooth muscle cell area.

    In plain wordsIn diabetic mice, carnosine did not significantly increase plaque smooth muscle cell area compared with no supplementation.

    Peptide
    L-carnosine
    Outcome
    No significant changeAlpha-actin-positive smooth muscle cell area
    Study

    micen: not reported in source

    diabetic apo E(-/-) mice
    Comparator
    no carnosine supplementation
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    2g/L · drinking water · 20 weeksAs given in this study (mice).

    Source sentences

    Summary
    The area occupied by α-actin-positive smooth muscle cells was not significantly increased.
    2 context sentences
    Summary · context
    Streptozotocin-induced diabetic apo E(-/-) mice were maintained for 20 weeks, post-induction of diabetes.
    Summary · context
    Half of the animals received carnosine (2g/L) in their drinking water.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.